COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01281007
Recruitment Status : Completed
First Posted : January 21, 2011
Results First Posted : July 7, 2015
Last Update Posted : July 7, 2015
Information provided by (Responsible Party):

Brief Summary:

Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as famciclovir and aciclovir.

This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with active recurrent genital herpes.

Condition or disease Intervention/treatment Phase
GENITAL HERPES Drug: Famciclovir Drug: Aciclovir Phase 3

Detailed Description:


  • Open-label, prospective, parallel group, intent to treat trial
  • Experiment duration: 5 days
  • 2 visits (days 1, and 5)
  • Reduction of symptoms
  • Adverse events evaluation

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes
Study Start Date : July 2012
Actual Primary Completion Date : January 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genital Herpes

Arm Intervention/treatment
Experimental: Famciclovir 125 mg
1 tablet every 12 hours for 5 days
Drug: Famciclovir
Famciclovir 125 mg every 12 hours for 5 days

Active Comparator: Aciclovir 200 mg
1 tablet every 4 hours (excluding nocturnal dose) for 5 days
Drug: Aciclovir
Aciclovir 200 mg every 4 hours fo 5 days

Primary Outcome Measures :
  1. Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation [ Time Frame: Day 5 ]
    Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.

Secondary Outcome Measures :
  1. Safety Will be Evaluated by the Adverse Events Occurence [ Time Frame: Day 5 ]
    Adverse events will be collected and followed in order to evaluate safety and tolerability

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients must be able to understand the study procedures agree to participate and give written consent.
  2. Patients with clinical diagnosis of recurrent genital herpes;
  3. Score symptoms higher than 4;
  4. Negative pregnant urine test.

Exclusion criteria:

  1. Pregnancy or risk of pregnancy.
  2. Lactation
  3. Any pathology or past medical condition that can interfere with this protocol.
  4. Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive drugs (in the last 30 days and during the study);
  5. Patients with immunodeficiency and/or immunosuppressive disease;
  6. Hypersensitivity to components of the formula;
  7. Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01281007

Layout table for location information
Centro de Medicina Reprodutiva Dr Carlos Isaia Filho Ltda
Porto Alegre, RS, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, RS, Brazil
Braganca Paulista, SP, Brazil
Caep Centro Avancado de Estudos E Pesquisas Ltda
Campinas, SP, Brazil
CEMICAMP - Centro de Pesquisas em Saúde Reprodutiva de Campinas
Campinas, SP, Brazil
CECIP - Centro de Estudos Clínicos do Interior Paulista
Jau, SP, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
Ribeirao Preto, SP, Brazil, 14048900
Instituto Sirio Libanes de Ensino e Pesquisa
Sao Paulo, SP, Brazil, 01308-060
Afip - Associacao Fundo de Incentivo A Psicofarmacologia
Sao Paulo, SP, Brazil
Sponsors and Collaborators
Layout table for investigator information
Study Director: Roberto Amazonas, MD EMS
Layout table for additonal information
Responsible Party: EMS Identifier: NCT01281007    
Other Study ID Numbers: F125EMS1010
First Posted: January 21, 2011    Key Record Dates
Results First Posted: July 7, 2015
Last Update Posted: July 7, 2015
Last Verified: July 2015
Keywords provided by EMS:
Herpes Simplex Virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Herpes Genitalis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Antiviral Agents
Anti-Infective Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action